Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITDAEPS (Basic)EPS (Weighted Average and Diluted)Income towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Summit Therapeutics (SMMT) Net Income towards Common Stockholders (2022 - 2024)

Summit Therapeutics' Net Income towards Common Stockholders history spans 3 years, with the latest figure at -$65.6 million for Q4 2024.

  • For Q4 2024, Net Income towards Common Stockholders fell 81.23% year-over-year to -$65.6 million; the TTM value through Sep 2025 reached -$65.6 million, up 68.03%, while the annual FY2024 figure was -$234.7 million, 61.84% up from the prior year.
  • Net Income towards Common Stockholders reached -$65.6 million in Q4 2024 per SMMT's latest filing, down from -$60.8 million in the prior quarter.
  • In the past five years, Net Income towards Common Stockholders ranged from a high of -$15.8 million in Q2 2023 to a low of -$537.2 million in Q1 2023.
  • Average Net Income towards Common Stockholders over 3 years is -$88.2 million, with a median of -$40.9 million recorded in 2023.
  • The largest YoY upside for Net Income towards Common Stockholders was 91.53% in 2024 against a maximum downside of 297.11% in 2024.
  • A 3-year view of Net Income towards Common Stockholders shows it stood at -$20.3 million in 2022, then tumbled by 78.38% to -$36.2 million in 2023, then tumbled by 81.23% to -$65.6 million in 2024.
  • Per Business Quant, the three most recent readings for SMMT's Net Income towards Common Stockholders are -$65.6 million (Q4 2024), -$60.8 million (Q3 2024), and -$62.7 million (Q2 2024).